Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by Chardan Capital in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $14.00 price target on the stock. Chardan Capital’s price target indicates a potential upside of 146.48% from the company’s previous close.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Coya Therapeutics in a research note on Monday, June 9th. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd. Lake Street Capital assumed coverage on shares of Coya Therapeutics in a report on Wednesday, July 9th. They set a “buy” rating and a $16.00 price target for the company. Finally, D. Boral Capital reiterated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a report on Thursday, July 24th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to data from MarketBeat, Coya Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $16.50.

Coya Therapeutics Trading Down 8.4%

NASDAQ:COYA opened at $5.68 on Wednesday. The company’s 50-day moving average price is $5.96 and its 200-day moving average price is $6.08. The company has a market cap of $95.03 million, a P/E ratio of -4.58 and a beta of 0.26. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last issued its earnings results on Tuesday, August 12th. The company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.14). The business had revenue of $0.16 million for the quarter, compared to the consensus estimate of $0.78 million. On average, analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new position in Coya Therapeutics during the 4th quarter worth approximately $74,000. Tower Research Capital LLC TRC lifted its position in shares of Coya Therapeutics by 1,005.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock worth $30,000 after buying an additional 4,777 shares during the last quarter. Northern Trust Corp lifted its position in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after buying an additional 3,099 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Coya Therapeutics by 5.8% during the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock worth $863,000 after buying an additional 8,267 shares during the last quarter. Finally, DME Capital Management LP lifted its position in shares of Coya Therapeutics by 29.2% during the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after buying an additional 372,414 shares during the last quarter. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.